{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-007065","form_type":"8-K","ticker":"QURE","cik":"0001590560","company_name":"uniQure N.V.","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.917360+00:00","generated_at":"2026-05-22T01:41:30.812417+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"uniQure Q1 net loss per share $0.82; AMT-130 granted FDA Breakthrough Therapy designation","bullets":["Net loss $43.6M ($0.82 per share) vs $65.6M ($1.36) in Q1 2024; revenue down to $1.6M from $8.5M.","Cash and investments $409M as of Mar 31, 2025; expects funding into H2 2027.","AMT-130 for Huntington's disease granted FDA Breakthrough Therapy designation in Apr 2025.","BLA submission guidance for AMT-130 expected in Q2 2025 after official meeting minutes.","Initial AMT-260 epilepsy data to be presented May 29, 2025; AMT-191 Fabry data in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-007065","json":"https://secwatch.observer/filing/0001558370-25-007065.json","markdown":"https://secwatch.observer/filing/0001558370-25-007065.md","text":"https://secwatch.observer/filing/0001558370-25-007065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590560/000155837025007065/0001558370-25-007065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590560/000155837025007065/qure-20250509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T01:41:30.812417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}